



Final Appraisal Recommendation
Advice No: 1217 – July 2017

Adalimumab (Humira®) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial)

Limited submission by AbbVie Ltd

Recommendation of AWMSG

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3371), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	AbbVie Ltd
Date of first issue	July 2017
Last reviewed	August 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1217:
Adalimumab (Humira®) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial).
July 2017